Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients
Prospective Phase II Study of Decitabine Induction Therapy to Reduce Pre-transplant Disease Burden Prior to Allogeneic Hematopoietic Cell Transplant in Patients With Newly Diagnosed Myelodysplastic Syndromes.
Allogeneic blood stem cell transplant remains the only potential curative treatment for myelodysplastic syndromes (MDS) to date. Pre-transplant induction chemotherapy with leukemia-type regimens is associated with significant toxicity and even death. The hypomethylating agents decitabine and 5-azacytidine have been shown in studies to cause improved hematologic parameters and partial or complete responses in patients with high risk MDS compared to standard therapy. In contrast to leukemia-type chemotherapy, decitabine is associated with a relatively low risk of toxicity. We therefore propose to treat transplant-eligible MDS patients with Decitabine as induction therapy and a bridge to transplant.
Hypothesis:
- Decitabine is able to reduce disease burden as measured by blood and marrow blast counts prior to allogeneic hematopoietic stem cell transplant to below 5%.
- Decitabine is well-tolerated by patients with high-risk MDS and will be a safe induction agent and bridge prior to allogeneic transplant in transplant-eligible patients.
研究概览
详细说明
Primary endpoint:
- safety and tolerability of Decitabine prior to transplant (assessed by occurence of non-hematologic toxicities of grade 3 or more as defined by CTC grading)
- reduction in pre-transplant disease burden ability to achieve blast <5% in the bone marrow and peripheral blood
Secondary endpoints:
- Proportion of patients with suitable donor able to proceed to an allogeneic hematopoietic cell transplant.
- Non-relapse mortality
- time to neutrophil engraftment
- Overall survival and disease-free survival.
Patients will receive Decitabine until blast <5% is achieved, suitable HLA-matched donor or umbilical cord blood is available up to a maximum of 6 cycles. Patient who progress on therapy or are unable to find a donor by 6 cycles will be removed from protocol. The method, conditioning regimen and choice of donor will be determined based on patient's age and functional status, and transplant physician's discretion. The available regimens are standardized within the center
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Singapore、新加坡、169608
- Singapore General Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Newly diagnosed MDS patients aged 21 to 65 years belonging to any of the following categories: refractory cytopenia with multilineage dysplasia (RCMD) with or without ringed sideroblasts (i.e. RCMD and RCMD-RS), refractory anemia with excess blasts-1 (RAEB-1) or RAEB-2 if the prognostic scores are IPSS (international prognostic scoring system) Int-2 or IPSS-high or with WPSS (WHO prognostic scoring system) 3 and above
- Therapy-related MDS with IPSS Int-2 and above or WPSS 3
- Acceptable cardiac function MUGA or Echocardiography left ventricular ejection fraction of 40% and above
- Acceptable lung function: FEV1>70% predicted, DLCO>60% predicted
- Acceptable renal function: CCT > 50ml/min
- Acceptable liver function: abnormalities in bilirubin or transaminases not > 2times upper limit of normal
- Performance status of ECOG 2 or HCT-specific Comorbidity Index < 3
Exclusion Criteria:
- Any co-morbidity other than MDS which limits life-expectancy to <3mth
- Diagnosis of other active cancer other than squamous cell carcinoma, basal cell carcinoma or carcinoma-in-situ 1 or 2 of the cervix
- Presence of active infections not under control
- Receipt of 5-azacytidine or other induction chemotherapy for MDS/AML
- Patients not keen to explore allogeneic HCT as part of curative treatment plan
- Pregnancy
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single Arm
Decitabine 20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
|
20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Reduction in pre-transplant disease burden
大体时间:2 years
|
2 years
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
无病生存
大体时间:3年
|
3年
|
|
Proportion of patients with suitable donor able to proceed to an allogeneic HCT
大体时间:2 years
|
2 years
|
|
Non-relapse mortality
大体时间:3 years
|
3 years
|
|
Time to neutrophil engraftment
大体时间:2 years
|
2 years
|
|
Overall survival survival
大体时间:3 years
|
3 years
|
合作者和调查者
调查人员
- 首席研究员:Aloysius Ho、Singapore General Hospital
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.